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Abstract 
The aim of this study was to determine whether Raman spectroscopy combined with 
chemometric analysis can be applied to interrogate biofluids (plasma, serum, saliva and urine) 
towards detecting oesophageal stages through to oesophageal adenocarcinoma 
(normal/squamous epithelium, inflammatory, Barrett´s, low-grade dysplasia [LGD], high-
grade dysplasia [HGD], and oesophageal adenocarcinoma [OAC]). The chemometric analysis 
of the spectral data was performed using principal component analysis (PCA), successive 
projections algorithm (SPA) or genetic algorithm (GA) followed by quadratic discriminant 
analysis (QDA). The GA-QDA model using a few selected wavenumbers for saliva and urine 
samples achieved 100% classification for all classes. For plasma and serum, the GA-QDA 
model achieved excellent accuracy in all oesophageal stages (>90%). The main GA-QDA 
features responsible for sample discrimination were: 1012 cm−1 (C-O stretching of ribose), 
1336 cm-1 (Amide III and CH2 wagging vibrations from glycine backbone), 1450 cm
-1 
(methylene deformation), and 1660 cm-1 (Amide I). The results of this study are promising 
and support the concept that Raman on biofluids may become a useful and objective 
diagnostic tool to identify oesophageal disease stages from squamous epithelium to OAC. 
 
Abbreviations: BO, Barrett’s oesophagus; CCD, charge-coupled device; GA, genetic 
algorithm; GA-QDA, genetic algorithm quadratic discriminant analysis; GI, gastro-intestinal, 
GORD, gastro-oesophageal reflux disease; HGD, high-grade dysplasia; LGD, low-grade 
dysplasia; OAC, oesophageal adenocarcinoma; PCA, principal component analysis; PCA-
QDA, principal component analysis quadratic discriminant analysis; QDA, quadratic 
discriminant analysis; SPA-QDA, successive projections algorithm quadratic discriminant 
analysis. 
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1 INTRODUCTION 
Barrett’s oesophagus (BO) is the only known precursor to oesophageal 
adenocarcinoma (OAC) to date as a result of chronic inflammation from gastro-oesophageal 
reflux disease (GORD). GORD increases the risk of OAC by greater than 40-fold compared 
with the general population [1]. At present there are no reliable predictive biomarkers that 
might enable us to risk-stratify BO patients and identify those who would benefit most from 
endoscopic management [2]. Early detection and prevention are the key strategies to manage 
OAC. Early detection of cancer or dysplasia in BO allows intervention at an early stage. The 
argument as to which BO patients are most likely to benefit from surveillance and 
management hinges on the high prevalence of BO and the low cancer incidence among 
unselected BO cases, versus the burden of invasive treatment and the high morbidity and 
mortality from OAC [3]. 
There is a continuing effort in the search of new technology that can detect early 
biochemical signs of malignancy and therefore significantly reduce morbidity and mortality. 
Biomarkers including carbohydrates, proteins, lipids and nucleic acids can be used for risk 
assessment, diagnosis, prognosis, and for the prediction of treatment efficacy [4]. Exploration 
of biofluids has only been recently explored by vibrational spectroscopic techniques [4]. They 
are easily accessible, minimally invasive and exhibit fingerprint spectra that have 
characteristic bands reflecting their biochemical structure. 
Raman spectroscopy is complementary to infrared (IR) technology and has 
advantageous properties when analysing biofluids. Contrary to conventional detection 
methods, optical spectroscopy on plasma, serum, saliva or urine provides an opportunity to 
diagnose diseases non-invasively. Raman spectroscopy is based on inelastic vibrational 
scattering, which can detect the secondary constitution of molecules [5]. No labelling is 
necessary and the technique provides high spectral sensitivity [6]. Spectroscopy on biofluids 
has been focused on plasma and serum analysis due to the large readily available biobanks in 
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research laboratories. Multiple studies have been performed demonstrating the potential of 
Raman spectroscopy for differentiating normal subjects from patients with colorectal [7], 
hepatocellular [8], cervical [9], and breast cancers [10]. Raman spectroscopy in serum has 
been performed to differentiate controls from oral cancers  (tongue cancers) [11]; however, to 
date, no research has been established using Raman spectroscopy to investigate oesophageal 
transformation to adenocarcinoma from human body fluids. 
This paper proposes an accurate, fast, and inexpensive method using biofluids (plasma, 
saliva, serum and urine) for detecting oesophageal stages through to OAC (normal; 
inflammatory; Barrett´s; low-grade dysplasia (LGD), high-grade dysplasia (HGD); and, OAC) 
using Raman spectroscopy. 
 
2 MATERIAL AND METHODS 
2.1 Sample Collection 
Patients were identified from Upper gastro-intestinal (GI) multi-disciplinary team 
meetings and pathology hospital databases which had been created by the Pathology 
Laboratory manager and one of the Consultant GI Histopathologists.  Potential patients were 
identified prospectively and consent for biofluids (blood for plasma and serum; urine and 
saliva) was taken between October 2017 and June 2019 in a clinic or endoscopy setting. The 
biofluid specimens were categorised as follows: i) plasma:  n=35 normal, n=18 inflammatory, 
n=27 Barrett´s, n=6 LGD, n=12 HGD and n=22 OAC (set A); ii) saliva: n=35 normal, n=18 
inflammatory, n=26 Barrett´s, n=5 LGD, n=10 HGD and n=24 OAC (set B); serum: n=36 
normal, n=19 inflammatory, n=28 Barrett´s, n=6 LGD, n=12 HGD and n=23 OAC (set C); 
and, urine: n=38 normal, n=19 inflammatory, n=27 Barrett´s, n=6 LGD, n=11 HGD and n=26 
OAC (set D). 
Ethical approval was granted by the East of England - Cambridge Central Research 
Ethics Committee from 2015 (Archival gastro-intestinal tissue, blood, saliva and urine 
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collection; REC reference: 18/EE/0069; IRAS project ID: 242639). Ethics was also granted 
from the parent University (STEMH 909 application). All biofluids taken at source patient 
contact were stored in their containers in the fridge at 4°C to 7°C. Prior to freezing, blood 
samples were centrifuged at 20°C at 2200 rpm for 15 min to obtain plasma and serum samples 
(local protocol). Saliva samples were taken from patients 3 to 6 h prior to ingestion of solids 
or liquids. All biofluids were then snap frozen and stored in the freezer at -80°C. 
Prior to slide preparation, biofluids samples were left to thaw in the fridge at 7°C. 
Thirty mL of individual biofluids (plasma, serum and saliva) were pipetted onto aluminium 
foil-lined FisherBrand™ slides for Raman spectroscopy analysis. Urine was centrifuged at 
2200 rpm at 20°C with the supernatant pipetted onto each slide. Each slide was labelled with 
a specific GI (Gastrointestinal number) used to anonymise samples. All slides were left to dry 
prior to transportation in wooden slide boxes to the spectroscopy laboratory for analysis. 
Samples were stored in a de-humidified glass container to prevent condensation and physical 
damage. 
2.2 Raman Spectroscopy 
Raman point spectra acquisition was performed with an InVia Renishaw Raman 
spectrometer coupled with a charge-coupled device (CCD) detector and a Leica microscope.  
A 200-mW laser diode was used at a wavelength of 785 nm with a grating of 1200 lines/mm. 
Exposure time was set at 10 s, with 5% laser power, and 2 accumulations at a spectral range 
between 2000−400 cm-1. Twenty-five point spectra were taken per sample using a 20× 
objective to focus the laser beam on the sample. 
2.3 Data Analysis and Chemometric Methods 
The data import, pre-treatment and construction of chemometric classification models 
(principal component analysis quadratic discriminant analysis [PCA-QDA], successive 
projections algorithm quadratic discriminant analysis [SPA-QDA] and genetic algorithm 
quadratic discriminant analysis [GA-QDA]) were implemented in MATLAB R2014a 
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software (MathWorks, USA) by using the PLS Toolbox version 7.9.3 (Eigenvector Research, 
Inc., USA) and laboratory-made routines. The raw spectra were pre-processed by cutting 
between 1800 and 800 cm-1 (939 wavenumbers at 4 cm-1 spectral resolution). Cosmic rays 
were corrected using the Renishaw WiRE software system, and baseline distortions due to 
fluorescence interference were corrected with the asymmetric least squares (ALS) baseline 
correction algorithm [12]. For PCA–QDA, SPA–QDA and GA–QDA models, the samples 
were divided into training (60%), validation (20%) and prediction sets (20%) by applying the 
classic Kennard–Stone (KS) uniform sampling algorithm [13] to the spectra as shown in 
Table 1. The optimum number of variables for SPA-QDA and GA-QDA were performed with 
an average risk G of QDA misclassification. Such a cost function was calculated in the 
validation set as: 
𝑮 =
𝟏
𝑵𝑽
∑ 𝒈𝒏
𝑵𝑽
𝒏=𝟏            (1) 
where 𝑵𝑽 is the number of validation spectra and 𝒈𝒏 is defined as: 
𝒈𝒏 =
𝒓𝟐(𝒙𝒏,𝒎𝑰(𝒏))
𝐦𝐢𝐧𝑰(𝒎)≠𝑰(𝒏) 𝒓𝟐(𝒙𝒏,𝒎𝑰(𝒎))
          (2) 
where 𝑰(𝒏) is the index of the true class for the nth validation object 𝒙𝒏. In this definition, the 
numerator is the squared Mahalanobis distance between object 𝒙𝒏 (of class index 𝑰(𝒏)) and 
the sample mean 𝒎𝑰(𝒏)  of its true class. The denominator in Eq. (2) corresponds to the 
squared Mahalanobis distance between object 𝒙𝒏 and the centre of the closest wrong class, 
𝒎𝑰(𝒎). The minimum value of the cost function (maximum fitness) will be achieved when the 
selected variables from the original data are as close as possible to its true class and more 
distance as possible from its wrong class according to the validation samples. The GA routine 
was carried out during 100 generations with 200 chromosomes each. Crossover and mutation 
probabilities were set to 60% and 1%, respectively. Moreover, the algorithm was repeated 
three times, starting from different random initial populations. The best solution (in terms of 
the fitness value) resulting from the three realisations of the GA was employed. 
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The calculation of classification quality parameters is a recommended standard 
practice for test evaluation [14]. For this study, measures of test accuracy, such as sensitivity 
(proportion of positive samples correctly identified), specificity (proportion of negative 
samples correctly identified) and F-score (measurement of the model accuracy), were utilised. 
These quality metrics were calculated as follows: 
Sensitivity (%) =
𝐓𝐏
𝐓𝐏+𝐅𝐍
× 𝟏𝟎𝟎         (3) 
Specificity (%) =  
𝐓𝐍
𝐓𝐍+𝐅𝐏
× 𝟏𝟎𝟎         (4) 
F-score =
𝟐×𝐒𝐄𝐍𝐒×𝐒𝐏𝐄𝐂
𝐒𝐄𝐍𝐒+𝐒𝐏𝐄𝐂
          (5) 
where TP stands for true positives, TN for true negatives, FP for false positives and FN for 
false negatives. SENS stands for sensitivity and SPEC for specificity. 
All selected wavenumbers obtained from SPA-QDA and GA-QDA for all oesophageal 
stages of disease (i.e., normal vs. inflammatory vs. Barrett´s vs. LGD vs. HGD vs. and OAC) 
were confirmed by a Student’s t-test (two-tailed, 95% confidence interval). 
 
3 RESULTS 
3.1 Plasma Dataset 
Fig. 1A shows the average raw Raman spectra derived from blood plasma for all 
groups (Normal vs. Inflammatory vs. Barrett’s vs. LGD vs. HGD vs. OAC), respectively. 
Raman spectra of all oesophagus sample stages were compared after cosmic rays and baseline 
correction. The shape and trend of the six groups were very similar: there are four main 
Raman peaks at the position at around 1004 cm−1, 1335 cm−1, 1450 cm−1 and 1660 cm-1 after 
fluorescence background removal (Figure 1B). Electron-rich groups (e.g., C═O, C═N, and 
C═C) are the major source of features in Raman spectroscopy [15], and many Raman peaks 
are caused by the same molecular functional group belonging to different biomolecules in the 
material [16]. However, there are still some visible spectral differences, notably the bands at 
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1004 cm−1 (collagen), 1335 cm−1 (CH3CH2 wagging mode of collagen), 1450 cm
-1 (methylene 
deformation) and 1660 cm-1 (Amide I). Most of these bands decrease in amplitude from the 
normal group to the OAC group. The difference between groups can be observed more clearly 
from the averaged pre-processed spectrum of each group (Figure 1B). After pre-processing of 
the spectral data, chemometric techniques (PCA-QDA, SPA-QDA and GA-QDA) were 
applied to systematically classify all groups based on their Raman spectra. 
The classification of the six oesophageal stages was developed by discriminant 
analysis using the Raman spectra between 800 and 1800 cm-1. The GA-QDA model with only 
16 variables (namely, 884 cm-1, 1188 cm-1, 1206 cm-1, 1235 cm-1, 1296 cm-1, 1307 cm-1, 1365 
cm-1, 1383 cm-1, 1402 cm-1, 1440 cm-1, 1461 cm-1, 1608 cm-1, 1641 cm-1, 1656 cm-1, 1715 cm-
1, and 1793 cm-1; Fig. 1C and 1D) was found to give the highest classification accuracy in 
comparison with the other methods (PCA-QDA and SPA-QDA). The classification rate in the 
test set for Inflammatory and Barrett’s samples using GA-QDA was equal to 100%. For the 
other classes, GA-QDA achieved accuracies, sensitivities and specificities above >85%. The 
PCA-QDA model using four PC scores (90% of the variance for all classes) achieved 100% 
accuracy, sensitivity, specificity and F-scores for LGD and OAC classes (Table 2). SPA-QDA 
also achieved a considerable high accuracy in classification of HGD (100%) when applied 
using 30 selected wavenumbers, as shown in Table 2. Table S1 lists the selected 
wavenumbers obtained with the GA-QDA model applied to the plasma samples along their 
respective tentative biomolecular assignments. 
3.2 Saliva Dataset 
Fig. 2A shows the average raw Raman spectra derived from saliva for all groups 
(Normal vs. Inflammatory vs. Barrett’s vs. LGD vs. HGD vs. OAC). Raman spectra of all 
stages of oesophageal disease were compared after cosmic rays and baseline correction. There 
are three main Raman peaks evident with the shape and trend similar for all groups: 1331 
cm−1, 1413 cm−1 and 1556 cm−1 in the raw spectra after fluorescence background removal 
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(Figure 2B). In particular, strong peaks observed in the pre-processed spectra at 1336 cm−1 
and 1664 cm−1 indicate Amide III and CH2 wagging vibrations from glycine backbone and 
Amide I, respectively. These peaks are inherent to Raman spectra of saliva [17]. Peaks at 852 
cm−1 and 1128 cm−1 correspond to C-N stretching, CH3 rocking and C-O vibrations, 
respectively. 
The classification of the six oesophageal stages was developed by discriminant 
analysis using the Raman pre-processed spectra between 800 and 1800 cm-1. The correct 
classification for the test set using GA-QDA was equal to 100% for all groups based on only 
16 selected wavenumbers (namely, 804 cm-1, 848 cm-1, 873 cm-1, 943 cm-1, 1012 cm-1, 1020 
cm-1, 1091 cm-1, 1163 cm-1, 1198 cm-1, 1326 cm-1, 1397 cm-1, 1404 cm-1, 1453 cm-1, 1528 cm-
1, 1552 cm-1 and 1765 cm-1), as shown in Figure 2C. An excellent classification by the GA-
QDA model for saliva was achieved (only 3 errors in the training set and 5 errors in the 
validation set) (Figure 2D). The PCA-QDA model using seven PC scores (90% of the 
variance for all classes) achieved good results specifically for inflammatory and HGD groups 
as can be seen in Table 3. In the SPA-QDA model, a considerable high accuracy in 
classification of OAC (100%) has been achieved using 30 selected wavenumbers (Table 3). 
Table S2 lists the selected wavenumbers obtained by GA-QDA for saliva samples with their 
tentative biomolecular assignments. 
3.3 Serum Dataset 
Fig. 3A shows the average raw Raman spectra derived from serum for all groups 
(Normal vs. Inflammatory vs. Barrett’s vs. LGD vs. HGD vs. OAC). There are three main 
Raman peaks with the shape and trend similar for all groups: 1327 cm−1, 1443 cm−1 and 1662 
cm−1 in the raw spectra after fluorescence background removal (Figure 3B). In particular, 
strong peaks observed in the pre-processed spectra at 1004, 1337, 1450 and 1657 cm−1 
indicate phenylalanine (proteins), Amide III, CH2 bending and Amide I, respectively. The 
PCA-QDA model using seven PC scores (95% of the variance for all classes) achieved good 
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results especially for inflammatory, HGD and OAC groups as can be seen in Table 4. Inr the 
SPA-QDA model, a considerable high accuracy in the classification of OAC (100%) was 
achieved using 30 selected wavenumbers. The correct classification for the test set using GA-
QDA was 100% for normal and HGD groups based on only 30 selected wavenumbers 
(namely, 821 cm-1, 842 cm-1, 894 cm-1, 962 cm-1, 989 cm-1, 1035 cm-1, 1042 cm-1, 1047 cm-1, 
1062 cm-1, 1132 cm-1, 1146 cm-1, 1162 cm-1, 1165 cm-1, 1249 cm-1, 1279 cm-1, 1282 cm-1, 
1321 cm-1, 1362 cm-1, 1402 cm-1, 1414 cm-1, 1415 cm-1, 1450 cm-1, 1471 cm-1, 1550 cm-1, 
1688 cm-1, 1711 cm-1, 1726 cm-1, 1727 cm-1, 1731 cm-1 and 1789 cm-1), as shown in Figure 
3C. The selected wavenumbers by GA-QDA for serum with their respective tentative 
assignment are listed in Table S3. 
3.4 Urine Dataset 
Fig. 4A shows the average raw Raman spectra derived from urine for all groups 
(Normal vs. Inflammatory vs. Barrett’s vs. LGD vs. HGD vs. OAC). The Raman spectra of all 
oesophageal disease stages were analysed after cosmic rays and baseline correction. There are 
two main Raman peaks with the shape and trend similar for all groups: 1012 cm−1 and 1340 
cm−1 in the raw spectra after fluorescence background removal (Figure 4B). In particular, 
strong peaks are observed in the pre-processed spectra at 1012 cm−1 and 1336 cm−1 indicating 
C-O stretching in ribose and polynucleotide chain (DNA purine bases), respectively. 
Classification of the six oesophageal stages was developed by discriminant analysis using the 
Raman spectra between 800 and 1800 cm-1. The correct classification for the test set using 
GA-LDA was equal to 100% for all groups based on only 29 selected wavenumbers (namely, 
845 cm-1, 849 cm-1, 858 cm-1, 864 cm-1, 877 cm-1, 997 cm-1, 1051 cm-1, 1089 cm-1, 1186 cm-1, 
1230 cm-1, 1231 cm-1,, 1248 cm-1,, 1320 cm-1, 1348 cm-1, 1374 cm-1, 1481 cm-1, 1565 cm-1, 
1580 cm-1, 1616 cm-1, 1681 cm-1, 1684 cm-1, 1704 cm-1, 1710 cm-1, 1719 cm-1, 1729 cm-1, 
1740 cm-1, 1763 cm-1 and 1791 cm-1), as can be seen in Figure 4C. The PCA-QDA model 
using six PC scores (93% of the variance for all classes) achieved good results specifically for 
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HGD and OAC groups (Table 3); and the SPA-QDA model achieved a considerable high 
accuracy (100%) for four classes (normal, inflammatory, Barrett’s and HGD) using 30 
selected wavenumbers (Table 3). Table S4 lists the selected wavenumbers obtained by GA-
QDA for urine plasma samples with their respective tentative biomolecular assignments. 
 
4 DISCUSSION 
There have been no studies using Raman vibrational spectroscopy on biofluids in 
order to identify stages of oesophageal transformation to OAC. This study has demonstrated 
that Raman spectroscopy coupled multivariate classification techniques (PCA-QDA, SPA-
QDA and GA-QDA) on biofluids can be used to identify oesophageal stages of disease to 
adenocarcinoma with excellent accuracy, sensitivity and specificity. A key finding from this 
study suggests an alteration of some main biomolecules such as tryptophan and phenylalanine 
from the control group (patients with normal squamous epithelium) to the adenocarcinoma 
group. These two substances have been shown to have an anti-cancer effect [18]. We presume 
that these two chemical components when present in plasma and serum are key factors that 
counteract with cancer cells; and they may increase oncogenic substances that induce cancer 
formation. In addition, spectral markers such as C-O stretching of ribose (1012 cm-1), Amide 
III and CH2 wagging vibrations from glycine backbone (1336 cm
-1), methylene deformation 
(1450 cm-1), and Amide I (1660 cm-1) were found as key discriminant features in saliva and 
urine between normal and progressive stages of oesophagus disease until cancer using GA-
QDA. Ribose sugars are precursors to biosynthetic pathways generated by the Warburg effect, 
which is responsible for keeping cancer cells alive by generating energy through glycolysis, 
where glucose is converted to lactose for energy followed by lactate fermentation even when 
oxygen is available [19]. Amide III vibrations attributed to β-sheet and α-helix conformation 
in proteins are highly associated to cancer [20-22]; as well as DNA methylation, which is an 
enzyme-induced chemical modification to the DNA structure where a methyl group is 
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covalently bonded to the cytosine base, and abnormalities in this phenomenon are related to 
carcinogenesis [23]. Amide I is known to be associated to cancer due to alterations in proteins 
backbone conformation [24]. 
Berger et al. [25] initially introduced the idea that Raman had potential for the analysis 
of biofluids. Biofluid assays have numerous advantages including high accessibility as well as 
low invasiveness. Sample processing is cheap and not laborious. This can be implemented in 
a clinical setting from routine investigations to intra-operative monitoring. In addition, Raman 
technology to analyse biofluids is particularly advantageous as samples do not need to be 
dried prior to analysis, which can change their biochemical composition. Raman spectroscopy 
has been performed on biofluid assays in a variety of cancer diagnostics. Taleb et al. [8] 
achieved an overall accuracy rate of 86–91% using multivariate analysis techniques applied to 
Raman spectral data of serum in hepatocellular carcinoma. Harvey et al. [26] conducted 
studies using Raman spectroscopy of urine to detect prostate cancer cells. The authors 
identified that the Raman spectra suggested a higher concentration of nucleic acids and 
proteins in bladder cells compared to the prostate cancer cells. An early work by Chan et al. 
[27] focused on analysing white blood cells as a potential diagnostic tool for haematological 
malignancies such as Lymphoma and Leukaemia. The authors showed that single-cell Raman 
micro-spectroscopy was able to discriminate between normal human lymphocytes and 
transformed Jurkat and Raji lymphocyte cell lines based on highly reproducible biomolecular 
fingerprints [27]. Multivariate statistical models based on the Raman spectra achieved a 
sensitivity of 98.3% for cancer detection, with 97.2% of the cells being correctly classified as 
belonging to the normal or transformed group [27]. 
Herein, the pre-processed Raman spectral datasets were analysed by classification 
methods based on QDA. QDA is a discriminant analysis algorithm based on a Mahalanobis 
distance calculation that uses a separate variance-covariance matrix for each class [28]. This 
increases the discrimination accuracy in complex biological medium where classes having 
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different variance structures are present [28]. PCA-QDA, SPA-QDA and GA-QDA were used 
on the six groups of samples for all biofluids separately. GA-QDA was found to be very 
effective in the discrimination between all groups, since this algorithm achieved a high-
quality performance rate using few wavenumbers. The GA-QDA model obtained an accuracy 
of 100% for saliva and urine in all groups. Although the number of samples in LGD and HGD 
groups are still small, which is a limitation towards the predictive ability of this classifier, the 
overall results demonstrate promising evidence that Raman spectroscopy coupled with 
chemometric techniques can be used for distinguish different stages of oesophagus disease to 
adenocarcinoma.  
In order to have a robust surveillance program for the early detection and improved 
detection rate for OAC, skilled endoscopists and pathologists are necessary for accurate 
mucosal sampling and histopathologic examination. However, the development of a quick, 
convenient, and inexpensive method for detecting early cancer or different stages from normal 
squamous epithelium through to OAC can be useful specifically to guide tissue biopsy thus 
increasing the yield of dysplasia detection. By using liquid samples the analysis would even 
be faster since no drying time would be necessary, and the level of discrimination could 
improve since relevant compounds might evaporate during the drying process. In addition, by 
using specially prepared slides for surface enhanced Raman spectroscopy the sensitivity of 
this method could be improved further due to the large magnification of the Raman signal for 
these samples [29]. This study shows the potential of Raman spectroscopy and chemometrics 
for detecting oesophageal stages of disease through to OAC based on biofluids with high 
accuracy, sensitivity and specificity. 
 
5 CONCLUSION 
Raman spectroscopy is a highly informative, non-destructive and robust technique that 
has been limitedly employed in the field of oesophageal disease. The results of this study 
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show that Raman spectroscopy coupled with multivariate classification algorithms (PCA-
QDA, SPA-QDA and GA-QDA) result in a powerful alternative approach for detection of 
oesophageal stages of disease to OAC in biofluids with an excellent accuracy, specificity and 
sensitivity in saliva and urine. We present a new, rational and convenient approach to 
different biofluids (plasma, saliva, serum and urine) using a minimal sample volume and 
without special sample preparation and reagents. This pilot study is pioneer; but further work 
in this field including larger cohorts of oesophageal malignancies samples should be 
performed in the future to validate these encouraging results before clinical trials. 
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SUPPORTING INFORMATION  
Additional Supporting Information may be found online in the supporting information tab for 
this article. 
Table S1:  Category-distinguishing wavenumbers for Normal vs. Inflammatory vs. Barrett’s vs. 
LGD vs. HGD vs. OAC using plasma samples obtained for SPA-QDA and GA-QDA models.  
Table S2: Category-distinguishing wavenumbers for Normal vs. Inflammatory vs. Barrett’s vs. 
LGD vs. HGD vs. OAC using saliva samples obtained for SPA-QDA and GA-QDA models. 
Table S3: Category-distinguishing wavenumbers for Normal vs. Inflammatory vs. Barrett’s vs. 
LGD vs. HGD vs. OAC using serum samples obtained for SPA-QDA and GA-QDA models. 
Table S4: Category-distinguishing wavenumbers for Normal vs. Inflammatory vs. Barrett’s vs. 
LGD vs. HGD vs. OAC using urine samples obtained for SPA-QDA and GA-QDA models. 
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FIGURES AND TABLES 
 
FIGURE 1. Comparison of Normal/Inflammatory/Barrett’s/LGD/HGD/OAC oesophageal 
stages using plasma samples for Raman spectroscopy. The panel shows: (A) Average raw 
Raman spectrum in the region between 1800 cm-1 and 800 cm-1; (B) Average pre-processed 
Raman spectrum obtained from all stages segregated into Normal (black colour) vs. 
Inflammatory (blue colour) vs. Barrett’s (green colour) vs. LGD (yellow colour) vs. HGD 
(magenta colour) vs. OAC (red colour); (C) 16 selected variables used by the GA-QDA 
model; (D) Samples vs. predicted class for training and test sets. The spectrum colour for each 
class in (A) and (B) are the same depicted in (D) inset.  
 
  
(a) (b)
(c) (d)
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FIGURE 2. Comparison of Normal/Inflammatory/Barrett’s/LGD/HGD/OAC oesophageal 
stages using saliva samples for Raman spectroscopy. The panel shows: (A) Average raw 
Raman spectrum in the region between 1800 cm-1 and 800 cm-1; (B) Average pre-processed 
Raman spectrum obtained from all stages segregated into Normal (black colour) vs. 
Inflammatory (blue colour) vs. Barrett’s (green colour) vs. LGD (yellow colour) vs. HGD 
(magenta colour) vs. OAC (red colour); (C) 16 selected variables used by the GA-QDA 
model; (D) Samples vs. predicted class for training and test sets. The spectrum colour for each 
class in (A) and (B) are the same depicted in (D) inset. 
  
(a) (b)
(c) (d)
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FIGURE 3. Comparison of Normal/Inflammatory/Barrett’s/LGD/HGD/OAC oesophageal 
stages using serum samples for Raman spectroscopy. The panel shows: (A) Average raw 
Raman spectrum in the region between 1800 cm-1 and 800 cm-1; (B) Average pre-processed 
Raman spectrum obtained from all stages segregated into Normal (black colour) vs. 
Inflammatory (blue colour) vs. Barrett’s (green colour) vs. LGD (yellow colour) vs. HGD 
(magenta colour) vs. OAC (red colour); (C) 30 selected variables used by the GA-QDA 
model; (D) Samples vs. predicted class for training and test sets. The spectrum colour for each 
class in (A) and (B) are the same depicted in (D) inset. 
  
(a) (b)
(c) (d)
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FIGURE 4. Comparison of Normal/Inflammatory/Barrett’s/LGD/HGD/OAC oesophageal 
stages using urine samples for Raman spectroscopy. The panel shows: (A) Average raw 
Raman spectrum in the region between 1800 cm-1 and 800 cm-1; (B) Average pre-processed 
Raman spectrum obtained from all stages segregated into Normal (black colour) vs. 
Inflammatory (blue colour) vs. Barrett’s (green colour) vs. LGD (yellow colour) vs. HGD 
(magenta colour) vs. OAC (red colour); (C) 29 selected variables used by the GA-QDA 
model; (D) Samples vs. predicted class for training and test sets. The spectrum colour for each 
class in (A) and (B) are the same depicted in (D) inset. 
 
 
  
 
(a) (b)
(c) (d)
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TABLE 1. Number of training, validation and prediction samples in each category of biofluids. 
Category – biofluids Training  Validation Test 
Normal – plasma 21 7 7 
Normal – serum 22 7 7 
Normal – saliva 21 7 7 
Normal – urine 23 7 8 
Inflammatory – plasma 11 3 4 
Inflammatory – serum 12 3 4 
Inflammatory – saliva 11 3 4 
Inflammatory – urine 12 3 4 
Barrett’s – plasma 16 5 6 
Barrett’s – serum 17 5 6 
Barrett’s – saliva 16 5 5 
Barrett’s – urine 17 5 5 
LGD – plasma 3 1 2 
LGD – serum 3 1 2 
LGD – saliva 2 1 2 
LGD – urine 3 1 2 
HGD – plasma 7 2 3 
HGD – serum 7 2 3 
HGD – saliva 7 2 3 
HGD – urine 7 3 3 
OAC – plasma 13 4 5 
OAC – serum 13 5 5 
OAC – saliva 14 5 5 
OAC – urine 15 5 6 
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TABLE 2. Figures of merit (accuracy, sensitivity, specificity and F-scores) for Normal vs. 
Inflammatory vs. Barrett’s vs. LGD vs. HGD vs. OAC using plasma samples. 
 
PCA-QDA 
 
Oesophageal stages 
Normal Inflammatory Barrett’s LGD HGD OAC 
Accuracy (%) 91.3 91.3 95.6 100 95.6 100 
Sensitivity (%) 100 90 100 100 95.2 100 
Specificity (%) 71.4 100 80 100 100 100 
F-Scores (%) 83.3 94.7 88.8 100 97.5 100 
 
SPA-QDA 
 
Oesophageal stages 
Normal Inflammatory Barrett’s LGD HGD OAC 
Accuracy (%) 82.6 86.9 95.6 95.6 100 86.4 
Sensitivity (%) 87.5 90 94.4 100 100 94.4 
Specificity (%) 71.4 66.6 100 100 100 60 
F-Scores (%) 78.6 76.6 97.1 73.3 100 73.3 
 
GA-QDA 
 
Oesophageal stages 
Normal Inflammatory Barrett’s LGD HGD OAC 
Accuracy (%) 95.2 100 100 91.3 95.6 91.3 
Sensitivity (%) 93.7 100 100 95.4 100 94.4 
Specificity (%) 100 100 100 100 70 80 
F-Scores (%) 96.7 100 100 83.3 66.6 86.6 
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TABLE 3. Figures of merit (FOM) (accuracy, sensitivity, specificity and F-scores) for Normal 
vs. Inflammatory vs. Barrett’s vs. LGD vs. HGD vs. OAC using saliva samples. 
 
 PCA-QDA 
 
Oesophageal stages 
Normal Inflammatory Barrett’s LGD HGD OAC 
Accuracy (%) 82.6 91.3 95.6 95.6 95.6 86.9 
Sensitivity (%) 87.5 90 100 100 95.2 94.4 
Specificity (%) 71.4 100 80 0 100 60 
F-Scores (%) 78.6 94.7 88.8 0 97.5 73.3 
 
SPA-QDA 
 
Oesophageal stages 
Normal Inflammatory Barrett’s LGD HGD OAC 
Accuracy (%) 95.6 95.6 95.6 95.6 91.3 100 
Sensitivity (%) 100 95 100 95.4 95.2 100 
Specificity (%) 85.7 100 80 100 50 100 
F-Scores (%) 92.3 97.4 88.8 97.6 65.5 100 
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TABLE 4. Figures of merit (FOM) (accuracy, sensitivity, specificity and F-scores) for Normal 
vs. Inflammatory vs. Barrett’s vs. LGD vs. HGD vs. OAC using serum samples. 
 
PCA-QDA 
 
Oesophageal stages 
Normal Inflammatory Barrett’s LGD HGD OAC 
Accuracy (%) 86.9 91.3 91.3 95.6 91.3 91.3 
Sensitivity (%) 93.7 90.0 100 100 90.4 94.4 
Specificity (%) 71.4 100 60 0 100 80.0 
F-Scores (%) 81.0 94.7 75 0 95 86.6 
 
SPA-QDA 
 
Oesophageal stages 
Normal Inflammatory Barrett’s LGD HGD OAC 
Accuracy (%) 95.6 95.6 91.3 95.6 86.9 100 
Sensitivity (%) 100 95.0 100 95.4 90.4 100 
Specificity (%) 85.7 100 60 100 50 100 
F-Scores (%) 92.3 97.4 75 97.6 64.4 100 
 
GA-QDA 
 
Oesophageal stages 
Normal Inflammatory Barrett’s LGD HGD OAC 
Accuracy (%) 100 95.6 95.6 95.6 100 95.6 
Sensitivity (%) 100 100 94.4 100 100 94.4 
Specificity (%) 100 66.6 100 60 100 100 
F-Scores (%) 100 80.0 97.1 70 100 97.2 
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TABLE 5. Figures of merit (accuracy, sensitivity, specificity and F-scores) for Normal vs. 
Inflammatory vs. Barrett’s vs. LGD vs. HGD vs. OAC using urine samples. 
 
PCA-QDA 
 
Oesophageal stages 
Normal Inflammatory Barrett’s LGD HGD OAC 
Accuracy (%) 62.5 66.7 83.3 95.8 87.5 87.5 
Sensitivity (%) 87.5 66.7 94.7 100 86.3 94.7 
Specificity (%) 12.5 66.7 40 0 100 60 
F-Scores (%) 21.8 66.7 56.2 0 92.7 73.4 
 
SPA-QDA 
 
Oesophageal stages 
Normal Inflammatory Barrett’s LGD HGD OAC 
Accuracy (%) 100 100 100 95.8 100 95.8 
Sensitivity (%) 100 100 100 100 100 94.7 
Specificity (%) 100 100 100 50 100 100 
F-Scores (%) 100 100 100 50 100 97.3 
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Graphical Abstract 
 
Four biofluids (plasma, serum, urine and saliva) were measured through Raman spectroscopy 
in order to detect oesophageal transformation stages to adenocarcinoma. 
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